stefan_berlin said:I did go to 2.4mg in the end, and the honest report is that it bought me less than the step before it and cost me two bad weeks.
This is my experience too, for whatever a second data point is worth. The detail I would add is minor and it is already implied above.
stefan_berlin said:I did go to 2.4mg in the end, and the honest report is that it bought me less than the step before it and cost me two bad weeks.
Adding the part of the answer the thread has not reached. Worth answering the question that was asked rather than the one behind it. The narrow version usually has an answer; the broad version usually does not, and answering the broad one is how a thread stops being useful.
One concrete data point for the thread. Give anything pharmacological four weeks before you judge it, and give anything measured weekly a four-point rolling average before you call it a trend.
PeptideDetective — Independent Peptide Analytics
Community-driven peptide testing and vendor rating platform. Transparent results. Unbiased analysis. Trusted by thousands.
View ResultsOne thing that is still open after stefan_berlin’s answer:
Whether anyone has held at a sub-maximal dose long term and kept the result, or whether the maintenance data only exists at 2.4mg?
dan_philly said:Give anything pharmacological four weeks before you judge it, and give anything measured weekly a four-point rolling average before you call it a…
I read this differently from dan_philly, on substance rather than tone. The objection nobody has made: this only works if the measurement is doing what we assume it is doing, and that assumption has not been tested here.
I would rather be corrected than agreed with, if it comes to it.